JPRN-jRCT2080220578未知2 期
Paricalcitol Injection Long-term Safety Study
Abbott Japan Co., Ltd.0 个研究点开始时间: 2008年7月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Aged 20 or over
- •Subjects allocated to paricalcitol groups in the phase IIb study (dose-response study) and completed it with good tolerability to paricalcitol injection
排除标准
- 未提供
研究者
相似试验
招募中
1 期
TS-FARMEV StudySolid tumors refractory to oncospecific treatment.RPCEC00000112Center for Genetic Engineering and Biotechnology (CIGB), in Havana.
已完成
不适用
Clinical pharmacological study for safety evaluation of ephedrine alkaloids-free Ephedra Herb extract (EFE) in healthy volunteersthose who are adapted Kampo formula which include Ephedra HerbJPRN-UMIN000022061Clinical Trial Center, Kitasato University Hospital12
进行中（未招募）
1 期
A long-term study to monitor the health status of people with cystic fibrosis who took part in a previous study with BI 3720931 (LenticlairTM-ON)MedDRA version: 20.0Level: PTClassification code: 10011763Term: Cystic fibrosis lung Class: 100000004850Cystic fibrosisCTIS2023-504909-37-00Boehringer Ingelheim International GmbH27
已完成
不适用
Clinical study to investigate the long-term safety and efficacy of human cell line recombinant Factor VIII (human-cl rhFVIII) in previously treated patients with severe haemophilia ASevere haemophilia AHaematological DisordersHereditary factor VIII deficiencyISRCTN90038418Octapharma AG (Switzerland)22
招募中
不适用
Clinical trial to evaluate safety and dose response of the C2 CryoBalloon 180 Ablation SystemBarrett's esophagus<br />Barrett's dysplasia<br />Cryoablation<br />Cryotherapy<br /><br />Barrett slokdarm<br />Barrett neoplasie<br />Cryoablatie<br />CryotherapieNL-OMON28028C2 Therapeutics, Inc.25